X-FAB Silicon Foundries (XFAB) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
30 Oct, 2026Executive summary
Q3 revenue was $194.4M, down 15% YoY and 3% QoQ; excluding IFRS 15 timing effects, revenue was $200.7M, down 12% YoY and up 2% QoQ.
Bookings rose 38% YoY and 30% QoQ to $224.7M, the highest in two years; backlog reached $313.6M and book-to-bill was 1.12.
Higher bookings and improving utilization support a gradual recovery across core markets.
Financial highlights
Q3 gross profit was $31.6M; operating profit was $4.3M, versus $23.8M a year earlier.
Net loss was $2.8M versus net profit of $16.6M in Q3 2025; EPS was -$0.02 versus $0.13.
9M revenue was $589.8M versus $648.0M; EBITDA was $105.3M versus $154.5M, and net loss was $16.7M versus net profit of $28.4M.
EBITDA was $37.5M, down 30% YoY and up 12% QoQ; margin was 19.3% reported and 18.6% excluding IFRS 15 effects.
Revenue recognized over time under IFRS 15 reduced Q3 reported revenue by $6.3M.
Outlook and guidance
Q4 revenue guidance is $205M–$215M and EBITDA margin guidance is 19%–22%, excluding IFRS 15 timing effects and assuming an average exchange rate of $1.14/€.
Q4 guidance is almost fully covered by backlog; typical order-to-revenue lag is three to five months, averaging four months.
Backlog visibility into 2027 extends to Q4 and partly Q1; fuller guidance is expected after Q4 results.
Site B end-of-life is expected around end-Q1/early-Q2 2027; last-time-buy orders are expected to reduce 2027 revenue by $50M against an $80M annual run rate.
FY 2026 net CapEx is projected at ~$100M; from 2026 onward, CapEx is targeted at 10%–15% of revenue.
Latest events from X-FAB Silicon Foundries
- Q2 2026 revenue fell up to 10% YoY, but bookings and medical growth signal recovery.XFAB
Q2 2026 - Q1 2026 revenue was $195.6M, with strong growth in industrial, medical, and microsystems.XFAB
Q1 2026 - Q4 revenue up 18% YoY to $222.3M; industrial and medical growth offset automotive softness.XFAB
Q4 2025 - Q3 2025 revenue up 12% YoY to $229M, led by industrial and medical growth; order intake fell.XFAB
Q3 2025 - Q2 revenue up 5–8% year-over-year, guidance raised, and capacity expansion completed.XFAB
Q2 2025 - Double-digit growth, major expansions, and $1.5B revenue and 35% margin targeted by 2030.XFAB
Investor Day 2024 - Q3 revenue up sequentially, automotive strong, industrial/medical weak, guidance lowered.XFAB
Q3 2024 - Q2 revenue fell 9% year-on-year; SiC weakness led to lower guidance, but Q4 rebound expected.XFAB
Q2 2024 - Q4 2024 revenue and profit fell amid auto destocking; CapEx to drop and recovery expected in 2025.XFAB
Q4 2024